6 studies were found.

1.		Recruiting	Phase I Study of gp75 Vaccine in Patients with Stage III and IV Melanoma Condition: Malignant Melanoma
2.		Recruiting	Phase II Study in Patients with EGFR + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer Conditions: Ovarian Cancer; Peritoneal Neoplasms; Fallopian Tube Neoplasms
3.		Recruiting	Phase III Study of Cetuximab, Oxaliplatin, 5-FU/LV vs. Oxaliplatin, 5-FU/LV in Patients with Previously Treated Metastatic, EGFR-Positive Colorectal Cancer Condition: Colorectal Cancer
4.		Recruiting	Phase III Study of Irinotecan and Cetuximab vs Irinotecan as Second-Line Treatment in Patients with Metastatic, EGFR-Positive Colorectal Cancer Condition: Colorectal Cancer
5.		Not yet recruiting	A Study in Patients with Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma Condition: Ovarian Cancer
6.		Recruiting	Study of Erbitux (cetuximab) Given Alone to Patients with EGFR-undetectable Metastatic Colon or Rectal Cancer that is Refractory to Chemotherapy Conditions: Colorectal Neoplasms; Metastases; Neoplasm